[{"id":"ef5ef83b-bc3d-4dc9-9b78-e271828de65e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06050122","created_at":"2023-09-22T14:10:44.436Z","updated_at":"2024-07-02T16:35:08.695Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome","source_id_and_acronym":"NCT06050122","lead_sponsor":"Sol-Gel Technologies, Ltd.","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patidegib topical (SGT-610)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/17/2024","start_date":" 03/17/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-19"},{"id":"a9577f45-e57c-4142-84ae-067eccfe367a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04007744","created_at":"2021-01-18T19:41:36.045Z","updated_at":"2024-07-02T16:35:12.692Z","phase":"Phase 1","brief_title":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04007744","lead_sponsor":"Mayo Clinic","biomarkers":" EGFR • PD-L1 • BRAF • ALK • MSI • BCL2 • BCL2L11","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["EGFR • PD-L1 • BRAF • ALK • MSI • BCL2 • BCL2L11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Odomzo (sonidegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/13/2020","start_date":" 02/13/2020","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-03-26"},{"id":"b2ee5075-c228-40d0-b9ee-e5526535926f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00878163","created_at":"2021-01-18T03:21:25.984Z","updated_at":"2024-07-02T16:35:15.360Z","phase":"Phase 1","brief_title":"GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT00878163","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gemcitabine • Erivedge (vismodegib) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 03/31/2009","start_date":" 03/31/2009","primary_txt":" Primary completion: 01/22/2013","primary_completion_date":" 01/22/2013","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-03-11"},{"id":"ffb94954-f1c1-4247-b33c-267b8f6f3014","acronym":"","url":"https://clinicaltrials.gov/study/NCT04231851","created_at":"2021-01-18T20:35:11.661Z","updated_at":"2024-07-02T16:35:20.841Z","phase":"Phase 2","brief_title":"CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia","source_id_and_acronym":"NCT04231851","lead_sponsor":"University of California, Irvine","biomarkers":" NPM1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyxeos (cytarabine/daunorubicin liposomal formulation) • Daurismo (glasdegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/19/2020","start_date":" 02/19/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-02-05"},{"id":"7d881018-0265-4ecb-9d18-1c4241cf9170","acronym":"","url":"https://clinicaltrials.gov/study/NCT05199584","created_at":"2022-01-20T14:53:33.589Z","updated_at":"2024-07-02T16:35:26.000Z","phase":"Phase 2","brief_title":"A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations","source_id_and_acronym":"NCT05199584","lead_sponsor":"Endeavor Biomedicines, Inc.","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e taladegib (ENV 101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 05/24/2022","start_date":" 05/24/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-12-18"},{"id":"aa1cebd7-d5ff-467e-9ba4-a573015d172c","acronym":"PersoMed-I","url":"https://clinicaltrials.gov/study/NCT04402073","created_at":"2021-01-18T21:14:10.343Z","updated_at":"2024-07-02T16:35:26.623Z","phase":"Phase 2","brief_title":"Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma","source_id_and_acronym":"NCT04402073 - PersoMed-I","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" TP53 • BRCA2 • MYCN","pipe":" | ","alterations":" TP53 wild-type • MYCN amplification","tags":["TP53 • BRCA2 • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • vincristine • lomustine • Odomzo (sonidegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 205","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2023-12-11"},{"id":"ec42b0ca-8ef6-412c-ad74-499ce7f4d1b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05538091","created_at":"2022-09-13T11:56:07.406Z","updated_at":"2024-07-02T16:35:27.786Z","phase":"Phase 2","brief_title":"Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer","source_id_and_acronym":"NCT05538091","lead_sponsor":"Ronald Buckanovich","biomarkers":" BRCA • CD4","pipe":"","alterations":" ","tags":["BRCA • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Erivedge (vismodegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 05/15/2023","start_date":" 05/15/2023","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2023-11-29"},{"id":"e1683f45-f260-4fe6-a1c8-c64aaf27d499","acronym":"EDALINE","url":"https://clinicaltrials.gov/study/NCT02027376","created_at":"2021-01-18T09:17:00.650Z","updated_at":"2025-02-25T15:41:12.890Z","phase":"Phase 1","brief_title":"Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients","source_id_and_acronym":"NCT02027376 - EDALINE","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Odomzo (sonidegib)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2023-04-03"},{"id":"2bb7d6c9-0473-46c7-9460-ae9487c6e000","acronym":"","url":"https://clinicaltrials.gov/study/NCT04679480","created_at":"2021-01-19T20:46:22.519Z","updated_at":"2024-07-02T16:36:00.949Z","phase":"Phase 2","brief_title":"Anti-PD1-antibody and Pulsed HHI for Advanced BCC","source_id_and_acronym":"NCT04679480","lead_sponsor":"Reinhard Dummer","biomarkers":" CD8 • PD-1 • CD4 • CD200 • FOXP3","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression • BCL2 expression • CD20 expression • CD200 expression","tags":["CD8 • PD-1 • CD4 • CD200 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression • BCL2 expression • CD20 expression • CD200 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Odomzo (sonidegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/18/2021","start_date":" 02/18/2021","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2022-11-04"},{"id":"f514e125-fc12-410e-8afb-782e274842a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04655391","created_at":"2021-01-19T20:41:28.630Z","updated_at":"2024-07-02T16:36:09.137Z","phase":"Phase 1b","brief_title":"Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT04655391","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • ABL1 • BCR • IDH1 • AXL","pipe":" | ","alterations":" IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836","tags":["FLT3 • ABL1 • BCR • IDH1 • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • bosutinib • decitabine • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Daurismo (glasdegib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/25/2022","start_date":" 06/25/2022","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2022-06-09"},{"id":"d06e8af1-41a9-44ee-8b8e-7998ed004a25","acronym":"","url":"https://clinicaltrials.gov/study/NCT03703310","created_at":"2021-01-18T18:08:53.199Z","updated_at":"2024-07-02T16:36:33.679Z","phase":"Phase 3","brief_title":"Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)","source_id_and_acronym":"NCT03703310","lead_sponsor":"PellePharm, Inc.","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patidegib topical (SGT-610)"],"overall_status":"Completed","enrollment":" Enrollment 174","initiation":"Initiation: 02/19/2019","start_date":" 02/19/2019","primary_txt":" Primary completion: 12/28/2020","primary_completion_date":" 12/28/2020","study_txt":" Completion: 12/28/2020","study_completion_date":" 12/28/2020","last_update_posted":"2021-03-08"},{"id":"dcfdfb8d-1bd6-45ea-82d2-226512a2eba5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01576666","created_at":"2021-01-18T06:42:34.232Z","updated_at":"2024-07-02T16:36:37.119Z","phase":"Phase 1","brief_title":"Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01576666","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e buparlisib (AN2025) • Odomzo (sonidegib)"],"overall_status":"Completed","enrollment":" Enrollment 120","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 04/01/2015","study_completion_date":" 04/01/2015","last_update_posted":"2020-12-19"},{"id":"b0e55042-5c0a-4922-b41d-814b4c0bc249","acronym":"","url":"https://clinicaltrials.gov/study/NCT01456676","created_at":"2022-04-24T08:55:35.467Z","updated_at":"2024-07-02T16:36:37.562Z","phase":"Phase 1","brief_title":"Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy","source_id_and_acronym":"NCT01456676","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib • Odomzo (sonidegib)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 02/01/2014","primary_completion_date":" 02/01/2014","study_txt":" Completion: 02/01/2014","study_completion_date":" 02/01/2014","last_update_posted":"2020-12-09"},{"id":"bb831b25-4b1e-44f8-a3dc-5bc7d5306158","acronym":"","url":"https://clinicaltrials.gov/study/NCT02354261","created_at":"2021-01-18T11:12:06.637Z","updated_at":"2024-07-02T16:36:42.308Z","phase":"Phase 2b","brief_title":"Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)","source_id_and_acronym":"NCT02354261","lead_sponsor":"HedgePath Pharmaceuticals, Inc.","biomarkers":" GLI1","pipe":" | ","alterations":" GLI1 expression","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itraconazole • Tolsura (SUBA-itraconazole)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 08/07/2015","start_date":" 08/07/2015","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2020-08-05"},{"id":"9d1cbdcb-bda6-4638-bfe0-b1a719e61280","acronym":"","url":"https://clinicaltrials.gov/study/NCT02762084","created_at":"2021-01-18T13:32:43.587Z","updated_at":"2024-07-02T16:36:42.846Z","phase":"Phase 2","brief_title":"Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients","source_id_and_acronym":"NCT02762084","lead_sponsor":"PellePharm, Inc.","biomarkers":" PTCH1 • GLI1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1 • GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patidegib topical (SGT-610)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 06/06/2016","start_date":" 06/06/2016","primary_txt":" Primary completion: 04/24/2017","primary_completion_date":" 04/24/2017","study_txt":" Completion: 04/24/2017","study_completion_date":" 04/24/2017","last_update_posted":"2020-07-23"},{"id":"96842ea0-1da9-4149-ba34-ced2a2b292bb","acronym":"BRIGHT AML","url":"https://clinicaltrials.gov/study/NCT01546038","created_at":"2024-01-07T00:16:58.018Z","updated_at":"2024-07-02T16:36:49.330Z","phase":"Phase 1b/2","brief_title":"A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT01546038 - BRIGHT AML","lead_sponsor":"Pfizer","biomarkers":" RUNX1","pipe":"","alterations":" ","tags":["RUNX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • daunorubicin • Daurismo (glasdegib)"],"overall_status":"Completed","enrollment":" Enrollment 255","initiation":"Initiation: 06/27/2012","start_date":" 06/27/2012","primary_txt":" Primary completion: 01/03/2017","primary_completion_date":" 01/03/2017","study_txt":" Completion: 03/04/2019","study_completion_date":" 03/04/2019","last_update_posted":"2020-03-03"},{"id":"56b9b02a-ad6f-4be1-aa31-c584f083e121","acronym":"","url":"https://clinicaltrials.gov/study/NCT02129101","created_at":"2021-01-18T09:52:18.475Z","updated_at":"2024-07-02T16:36:54.150Z","phase":"Phase 1","brief_title":"Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies","source_id_and_acronym":"NCT02129101","lead_sponsor":"Mayo Clinic","biomarkers":" JAK2","pipe":"","alterations":" ","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • decitabine • Odomzo (sonidegib)"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 10/25/2019","study_completion_date":" 10/25/2019","last_update_posted":"2019-10-30"},{"id":"fb5922c2-88de-441b-8c08-5a08e614bed9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01919398","created_at":"2021-01-18T08:39:32.118Z","updated_at":"2024-07-02T16:36:55.807Z","phase":"Phase 1","brief_title":"A Study of LY2940680 in Japanese Participants With Advanced Cancers","source_id_and_acronym":"NCT01919398","lead_sponsor":"Eli Lilly and Company","biomarkers":" GLI1","pipe":"","alterations":" ","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e taladegib (ENV 101)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 08/01/2013","start_date":" 08/01/2013","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 06/28/2017","study_completion_date":" 06/28/2017","last_update_posted":"2019-09-11"},{"id":"b9a2bdff-ff07-4e10-adff-f14635a883a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02111187","created_at":"2021-01-18T09:45:47.717Z","updated_at":"2024-07-02T16:37:02.137Z","phase":"Phase 1","brief_title":"A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer","source_id_and_acronym":"NCT02111187","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" GLI1","pipe":" | ","alterations":" GLI1 expression","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Odomzo (sonidegib)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 01/18/2017","primary_completion_date":" 01/18/2017","study_txt":" Completion: 01/18/2017","study_completion_date":" 01/18/2017","last_update_posted":"2019-03-07"},{"id":"eb9d7533-26cc-4fc3-b452-3eeed4ed6f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT02828111","created_at":"2021-01-18T13:51:59.563Z","updated_at":"2024-07-02T16:37:04.121Z","phase":"Phase 2","brief_title":"Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas","source_id_and_acronym":"NCT02828111","lead_sponsor":"PellePharm, Inc.","biomarkers":" GLI1","pipe":"","alterations":" ","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patidegib topical (SGT-610)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 11/11/2016","start_date":" 11/11/2016","primary_txt":" Primary completion: 11/09/2017","primary_completion_date":" 11/09/2017","study_txt":" Completion: 11/09/2017","study_completion_date":" 11/09/2017","last_update_posted":"2019-01-08"},{"id":"79383924-a193-49a9-829a-e82787434ada","acronym":"","url":"https://clinicaltrials.gov/study/NCT02115828","created_at":"2021-01-18T09:47:28.933Z","updated_at":"2024-07-02T16:37:08.789Z","phase":"Phase 1","brief_title":"A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy","source_id_and_acronym":"NCT02115828","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" AKT1 • GLI1","pipe":" | ","alterations":" GLI1 expression","tags":["AKT1 • GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erivedge (vismodegib)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2018-07-20"},{"id":"801546e5-690b-45d4-91eb-788913d198fc","acronym":"SHH-CM","url":"https://clinicaltrials.gov/study/NCT02694224","created_at":"2021-01-18T13:09:09.118Z","updated_at":"2025-02-25T16:30:46.376Z","phase":"Phase 2","brief_title":"Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT02694224 - SHH-CM","lead_sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • cyclophosphamide • epirubicin • Erivedge (vismodegib)"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2017-10-24"},{"id":"00c91ab4-92f1-495c-8d93-32c76994ed4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00980343","created_at":"2021-01-18T03:49:30.966Z","updated_at":"2024-07-02T16:37:18.798Z","phase":"Phase 2","brief_title":"GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery","source_id_and_acronym":"NCT00980343","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ","pipe":"","alterations":" ","tags":["Erivedge (vismodegib)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 02/01/2010","start_date":" 02/01/2010","primary_txt":" Primary completion: 05/01/2012","primary_completion_date":" 05/01/2012","study_txt":" Completion: 06/01/2012","study_completion_date":" 06/01/2012","last_update_posted":"2017-08-16"},{"id":"ef8dc717-a1f6-482f-b962-296b47ecd4a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01195415","created_at":"2021-01-18T04:47:05.372Z","updated_at":"2024-07-02T16:37:19.135Z","phase":"Phase 2","brief_title":"Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer","source_id_and_acronym":"NCT01195415","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD24","pipe":"","alterations":" ","tags":["CD24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Erivedge (vismodegib)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 10/10/2014","study_completion_date":" 10/10/2014","last_update_posted":"2017-08-07"}]